<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01204671</url>
  </required_header>
  <id_info>
    <org_study_id>114269</org_study_id>
    <nct_id>NCT01204671</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity Study of GSK Biologicals' Seasonal Influenza Candidate Vaccine (GSK2321138A)</brief_title>
  <official_title>Partially-blind Immunogenicity and Safety Study of GSK Biologicals' Seasonal Influenza Vaccine GSK2321138A in Adults.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      This study is designed to assess the safety and immunogenicity of a GSK Biologicals'
      investigational vaccine GSK2321138A in adults 18 years old and older. This study is also
      designed to assess the lot-to-lot consistency of vaccine GSK2321138A. The blinding will be
      double blind for all groups except for the GSK2604409A Group which will be open.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Titers for Hemagglutination Inhibition (HI) Antibodies Against 4 Strains of Influenza Disease</measure>
    <time_frame>At Day 0 (D0), and at Day 21 (D21)</time_frame>
    <description>Titers are presented as geometric mean titers (GMTs). The reference cut-off value was 1:10. HI antibodies assessed were antibodies against the A/California/7/2009 (H1N1), A/Victoria/210/2009 (H3N2), B/Brisbane/60/2008 (Victoria), and B/Brisbane/3/2007 (Yamagata) flu strains. Subjects receiving the GSK2321138A vaccine were pooled for this outcome measure.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Seroconverted Subjects Against 4 Strains of Influenza Disease</measure>
    <time_frame>At Day 21 (D21)</time_frame>
    <description>A seroconverted subject was a vaccinated subject who had either a pre-vaccination hemagglutination inhibition (HI) antibody titer &lt; 1:10 and a post-vaccination titer above or equal (&gt;=) 1:40, or a pre-vaccination HI antibody titer &gt;= 1:10 and at least a 4-fold increase in post-vaccination HI antibody titer. Antibodies assessed were HI antibodies against the A/California/7/2009 (H1N1), A/Victoria/210/2009 (H3N2), B/Brisbane/60/2008 (Victoria), and B/Brisbane/3/2007 (Yamagata) flu strains. Subjects receiving the GSK2321138A vaccine were pooled for this outcome measure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Seropositive Subjects Against 4 Strains of Influenza Disease</measure>
    <time_frame>At Day 0 (D0), and at Day 21 (D21)</time_frame>
    <description>A seropositive subject was a vaccinated subject with hemagglutination inhibition (HI) antibody titer above or equal (&gt;=) the reference cut-off value of 1:10. Antibodies assessed were HI antibodies against the A/California/7/2009 (H1N1), A/Victoria/210/2009 (H3N2), B/Brisbane/60/2008 (Victoria), and B/Brisbane/3/2007 (Yamagata) flu strains. Subjects receiving the GSK2321138A vaccine were pooled for this outcome measure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Seroprotected Subjects Against 4 Strains of Influenza Disease</measure>
    <time_frame>At Day 0 (D0), and at Day 21 (D21)</time_frame>
    <description>A seroprotected subject was a vaccinated subject who had hemagglutination inhibition (HI) antibody titer above or equal (&gt;=) 1:40. Antibodies assessed were HI antibodies against the A/California/7/2009 (H1N1), A/Victoria/210/2009 (H3N2), B/Brisbane/60/2008 (Victoria), and B/Brisbane/3/2007 (Yamagata) flu strains. Subjects receiving the GSK2321138A vaccine were pooled for this outcome measure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Increase in Hemagglutination Inhibition Antibodies Against 4 Strains of Influenza Disease</measure>
    <time_frame>At Day 21 (D21)</time_frame>
    <description>Increase in hemagglutination inhibition (HI) antibodies is presented in terms of mean geometric increase (MGI), defined as the geometric mean of the within subject ratios of the post-vaccination reciprocal HI titer to the Day 0 reciprocal HI titer , expressed using &quot;fold increase&quot; as unit . Antibodies assessed were HI antibodies against the A/California/7/2009 (H1N1), A/Victoria/210/2009 (H3N2), B/Brisbane/60/2008 (Victoria), and B/Brisbane/3/2007 (Yamagata) flu strains. Subjects receiving the GSK2321138A vaccine were pooled for this outcome measure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Any and Grade 3 Solicited Local Symptoms.</measure>
    <time_frame>Within the 7-day (Days 0-6) follow-up period after vaccination</time_frame>
    <description>Assessed solicited local symptoms post vaccination were pain, redness and swelling at the injection site. Any = occurrence of a symptom regardless of intensity. Grade 3 pain = significant pain at rest/ that prevented normal every day activities. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Days With Solicited Local Symptoms</measure>
    <time_frame>Within the 7-day (Days 0-6) follow-up period after vaccination</time_frame>
    <description>Assessed solicited local symptoms post vaccination were pain, redness and swelling at the injection site.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms</measure>
    <time_frame>Within the 7-day (Days 0-6) follow-up period after vaccination</time_frame>
    <description>Assessed solicited general symptoms post vaccination were fatigue, gastrointestinal symptoms (Gastr.), headache, joint pain at other location (Joint Pain), muscle aches, shivering, and temperature [axillary temperature above or equal to (&gt;=) 37.5 degrees Celsius (°C)]. Any = occurrence of a symptom regardless of intensity or relationship to vaccination. Grade 3 = symptom which prevented normal every day activities. Grade 3 temperature = axillary temperature &gt; 39°C. Related = symptom assessed as causally related to study vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Days With Solicited General Symptoms</measure>
    <time_frame>Within the 7-day (Days 0-6) follow-up period after vaccination</time_frame>
    <description>Assessed solicited general symptoms post vaccination were fatigue, gastrointestinal symptoms (Gastr.), headache, joint pain at other location (Joint Pain), muscle aches, shivering, and temperature [defined as axillary temperature above or equal to (&gt; =) 37.5 degrees Celsius (°C)].</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)</measure>
    <time_frame>Within the 21-day (Days 0-20) follow-up period after vaccination</time_frame>
    <description>Unsolicited AEs cover any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any unsolicited AE = any unsolicited AE regardless of intensity or relationship to vaccination. Grade 3 unsolicited AE = unsolicited AE that prevented normal everyday activity Related unsolicited AE = unsolicited AE assessed by the investigator as related to the vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Any and Related Adverse Events With Medically-attended Events (MAEs)</measure>
    <time_frame>From the beginning of the study (Day 0) to study end (Day 180)</time_frame>
    <description>Medically-attended events (MAEs) refer to non-serious and serious events leading to an otherwise unscheduled visit to or from medical personnel for any reason, including emergency room visits. If a MAE was leading to hospitalisation (or met any other serious adverse event criterion), it was reported as serious adverse event. Related MAE = MAE assessed by the investigator as related to the vaccination. Subjects receiving the GSK2321138A vaccine were pooled for this outcome measure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Any and Related Potential Immune-mediated Diseases (pIMDs)</measure>
    <time_frame>From the beginning of the study (Day 0) to study end (Day 180)</time_frame>
    <description>Potential immune-mediated diseases (pIMDs) are a subset of adverse events that include both clearly autoimmune diseases and also other inflammatory and/or neurologic disorders which may or may not have an autoimmune etiology. Related pIMD = pIMD assessed by the investigator as related to the vaccination. Subjects receiving the GSK2321138A vaccine were pooled for this outcome measure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Any and Related Serious Adverse Events (SAEs)</measure>
    <time_frame>From the beginning of the study (Day 0) to study end (Day 180)</time_frame>
    <description>Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject. Any SAE = any SAE regardless of intensity or relationship to vaccination. Related SAE = SAE assessed by the investigator as related to the vaccination.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">4659</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>GSK2321138A Lot 1 Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received one dose of the GSK2321138A vaccine, Lot 1, at Day 0. The GSK2321138A vaccine was administered as a single dose intramuscularly in the deltoid region of the non-dominant arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GSK2321138A Lot 2 Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received one dose of the GSK2321138A vaccine, Lot 2, at Day 0. The GSK2321138A vaccine was administered as a single dose intramuscularly in the deltoid region of the non-dominant arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GSK2321138A Lot 3 Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received one dose of the GSK2321138A vaccine, Lot 3, at Day 0. The GSK2321138A vaccine was administered as a single dose intramuscularly in the deltoid region of the non-dominant arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fluarix Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects received one dose of the Fluarix™ vaccine at Day 0. The Fluarix™ vaccine was administered as a single dose intramuscularly in the deltoid region of the non-dominant arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GSK2604409A Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects received one dose of the GSK2604409A vaccine at Day 0. The GSK2604409A vaccine was administered as a single dose intramuscularly in the deltoid region of the non-dominant arm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Influenza vaccine GSK2321138A</intervention_name>
    <description>One intramuscular injection</description>
    <arm_group_label>GSK2321138A Lot 1 Group</arm_group_label>
    <arm_group_label>GSK2321138A Lot 2 Group</arm_group_label>
    <arm_group_label>GSK2321138A Lot 3 Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>FluarixTM</intervention_name>
    <description>One intramuscular injection</description>
    <arm_group_label>Fluarix Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Influenza vaccine GSK2604409A</intervention_name>
    <description>One intramuscular injection</description>
    <arm_group_label>GSK2604409A Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A male or female 18 years of age or older at the time of the first vaccination

          -  Subjects who the investigator believes can and will comply with the requirements of
             the protocol.

          -  Written informed consent obtained from the subject.

          -  Healthy subjects or those with chronic well-controlled disease as established by
             physical examination before entering into the study.

          -  Female subjects of non-childbearing potential may be enrolled in the study.

          -  Female subjects of childbearing potential may be enrolled in the study, if the
             subject:

          -  - has practiced adequate contraception for 30 days prior to vaccination,

          -  - and has a negative urine pregnancy test on the day of vaccination,

          -  and has agreed to continue adequate contraception during the entire treatment period
             and for 2 months after completion of the vaccination series

        Exclusion Criteria:

          -  Use of any investigational or non-registered product other than the study vaccine
             within 30 days preceding the dose of the study vaccine or planned use during the study
             period.

          -  Chronic administration of immunosuppressants or other immune-modifying drugs within
             three months prior to enrolment in this study or planned administration during the
             study period.

          -  Administration of an influenza vaccine during the 6 months preceding entry into the
             study.

          -  Planned administration / administration of a vaccine not foreseen by the study
             protocol within 30 days before vaccination and up to Day 21.

          -  Any contra-indication to intramuscular administration of the influenza vaccines.

          -  History of hypersensitivity/anaphylaxis to a previous dose of influenza vaccine,
             history of any reaction or hypersensitivity likely to be exacerbated by any component
             of the vaccines.

          -  Any administration of a long-acting immune-modifying drug within 3 months before study
             start, or planned administration during the study period.

          -  Any confirmed or suspected immunosuppressive or immunodeficient condition, based on
             medical history and physical examination.

          -  Acute disease and/or fever at the time of enrolment.

          -  Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic or renal
             functional abnormality, as determined by physical examination or laboratory screening
             tests.

          -  History of Guillain-Barré syndrome within 6 weeks of receipt of prior inactivated
             influenza virus vaccine.

          -  Administration of immunoglobulins and/or any blood products within the three months
             prior to the enrolment in this study, or planned during the study.

          -  History of chronic alcohol consumption and/or drug abuse.

          -  Any condition which, in the opinion of the investigator, prevents the subject from
             participating in the study

          -  Pregnant or lactating female.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <zip>85224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Newton</city>
        <state>Kansas</state>
        <zip>67114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40509</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Columbia</city>
        <state>Maryland</state>
        <zip>21045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Milford</city>
        <state>Massachusetts</state>
        <zip>01757</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Salisbury</city>
        <state>North Carolina</state>
        <zip>28144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Erie</city>
        <state>Pennsylvania</state>
        <zip>16506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tuebingen</city>
        <state>Baden-Wuerttemberg</state>
        <zip>72074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Augsburg</city>
        <state>Bayern</state>
        <zip>86150</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Haag</city>
        <state>Bayern</state>
        <zip>83527</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Finsterwalde</city>
        <state>Brandenburg</state>
        <zip>03238</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Frankfurt am Main</city>
        <state>Hessen</state>
        <zip>60596</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mainz</city>
        <state>Rheinland-Pfalz</state>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dresden</city>
        <state>Sachsen</state>
        <zip>01277</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dresden</city>
        <state>Sachsen</state>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dresden</city>
        <state>Sachsen</state>
        <zip>01309</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Freiberg</city>
        <state>Sachsen</state>
        <zip>09599</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>10367</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>13086</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Guro Gu</city>
        <zip>152703</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gyeonggi</city>
        <zip>442-723</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Incheon</city>
        <zip>400-711</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>150-719</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Braila</city>
        <zip>810384</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Brasov</city>
        <zip>500260</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bucharest</city>
        <zip>020142</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bucharest</city>
        <zip>062289</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bucharest</city>
        <zip>077190</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Galati</city>
        <zip>800494</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Galati</city>
        <zip>800578</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pantelimon</city>
        <zip>77145</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ploiesti</city>
        <zip>100172</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Balenyà (Barcelona)</city>
        <zip>08550</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Centelles</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>La Roca del Valles (Barcelona)</city>
        <zip>08430</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Vic/ Barcelona</city>
        <zip>08500</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Taichung</city>
        <zip>404</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Korea, Republic of</country>
    <country>Romania</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 16, 2010</study_first_submitted>
  <study_first_submitted_qc>September 16, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 17, 2010</study_first_posted>
  <results_first_submitted>December 13, 2012</results_first_submitted>
  <results_first_submitted_qc>May 9, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 17, 2013</results_first_posted>
  <disposition_first_submitted>July 23, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>July 23, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">July 31, 2012</disposition_first_posted>
  <last_update_submitted>February 23, 2017</last_update_submitted>
  <last_update_submitted_qc>February 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>influenza infection</keyword>
  <keyword>GSK Biologicals influenza vaccine GSK2321138A</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>114269</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>114269</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>114269</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>114269</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>114269</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>114269</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>114269</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 4659 subjects (all aged 18 years and older at the time of their first vaccination as part of this study) were enrolled in this study, of which 4656 were vaccinated. The study vaccine dose was not administrated but subject number was allocated for the other 3 subjects.</recruitment_details>
      <pre_assignment_details>Subjects receiving the GSK2321138A and Fluarix™ vaccines were followed in a double-blinded manner throughout the entire study period, from Day 0 to Day 180. Subjects receiving the GSK2604409A vaccine were followed in an open manner until Day 21 only.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>GSK2321138A Lot 1 Group</title>
          <description>Subjects received one dose of the GSK2321138A vaccine, Lot 1, at Day 0. The GSK2321138A vaccine was administered as a single dose intramuscularly in the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="P2">
          <title>GSK2321138A Lot 2 Group</title>
          <description>Subjects received one dose of the GSK2321138A vaccine, Lot 2, at Day 0. The GSK2321138A vaccine was administered as a single dose intramuscularly in the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="P3">
          <title>GSK2321138A Lot 3 Group</title>
          <description>Subjects received one dose of the GSK2321138A vaccine, Lot 3, at Day 0. The GSK2321138A vaccine was administered as a single dose intramuscularly in the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="P4">
          <title>Fluarix Group</title>
          <description>Subjects received one dose of the Fluarix™ vaccine at Day 0. The Fluarix™ vaccine was administered as a single dose intramuscularly in the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="P5">
          <title>GSK2604409A Group</title>
          <description>Subjects received one dose of the GSK2604409A vaccine at Day 0. The GSK2604409A vaccine was administered as a single dose intramuscularly in the deltoid region of the non-dominant arm.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1012"/>
                <participants group_id="P2" count="1013"/>
                <participants group_id="P3" count="1011"/>
                <participants group_id="P4" count="1010"/>
                <participants group_id="P5" count="610"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="998"/>
                <participants group_id="P2" count="998"/>
                <participants group_id="P3" count="998"/>
                <participants group_id="P4" count="997"/>
                <participants group_id="P5" count="606"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="13"/>
                <participants group_id="P5" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unknown Completion Status</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>GSK2321138A Lot 1 Group</title>
          <description>Subjects received one dose of the GSK2321138A vaccine, Lot 1, at Day 0. The GSK2321138A vaccine was administered as a single dose intramuscularly in the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="B2">
          <title>GSK2321138A Lot 2 Group</title>
          <description>Subjects received one dose of the GSK2321138A vaccine, Lot 2, at Day 0. The GSK2321138A vaccine was administered as a single dose intramuscularly in the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="B3">
          <title>GSK2321138A Lot 3 Group</title>
          <description>Subjects received one dose of the GSK2321138A vaccine, Lot 3, at Day 0. The GSK2321138A vaccine was administered as a single dose intramuscularly in the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="B4">
          <title>Fluarix Group</title>
          <description>Subjects received one dose of the Fluarix™ vaccine at Day 0. The Fluarix™ vaccine was administered as a single dose intramuscularly in the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="B5">
          <title>GSK2604409A Group</title>
          <description>Subjects received one dose of the GSK2604409A vaccine at Day 0. The GSK2604409A vaccine was administered as a single dose intramuscularly in the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1012"/>
            <count group_id="B2" value="1013"/>
            <count group_id="B3" value="1011"/>
            <count group_id="B4" value="1010"/>
            <count group_id="B5" value="610"/>
            <count group_id="B6" value="4656"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.7" spread="17.90"/>
                    <measurement group_id="B2" value="58.0" spread="17.41"/>
                    <measurement group_id="B3" value="57.9" spread="17.80"/>
                    <measurement group_id="B4" value="58.1" spread="17.83"/>
                    <measurement group_id="B5" value="58.1" spread="17.92"/>
                    <measurement group_id="B6" value="58.0" spread="17.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="598"/>
                    <measurement group_id="B2" value="578"/>
                    <measurement group_id="B3" value="569"/>
                    <measurement group_id="B4" value="548"/>
                    <measurement group_id="B5" value="343"/>
                    <measurement group_id="B6" value="2636"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="414"/>
                    <measurement group_id="B2" value="435"/>
                    <measurement group_id="B3" value="442"/>
                    <measurement group_id="B4" value="462"/>
                    <measurement group_id="B5" value="267"/>
                    <measurement group_id="B6" value="2020"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Titers for Hemagglutination Inhibition (HI) Antibodies Against 4 Strains of Influenza Disease</title>
        <description>Titers are presented as geometric mean titers (GMTs). The reference cut-off value was 1:10. HI antibodies assessed were antibodies against the A/California/7/2009 (H1N1), A/Victoria/210/2009 (H3N2), B/Brisbane/60/2008 (Victoria), and B/Brisbane/3/2007 (Yamagata) flu strains. Subjects receiving the GSK2321138A vaccine were pooled for this outcome measure.</description>
        <time_frame>At Day 0 (D0), and at Day 21 (D21)</time_frame>
        <population>The analysis was performed on the According-to-Protocol cohort for Immunogenicity, which included all vaccinated and eligible subjects for whom data concerning immunogenicity outcome measures were available, and for whom assay results were available for antibodies against at least 1 study vaccine antigen component after vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2321138A Group</title>
            <description>Subjects received one dose of the GSK2321138A vaccine, Lot 1, 2 or 3, at Day 0. The GSK2321138A vaccine was administered as a single dose intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Group</title>
            <description>Subjects received one dose of the Fluarix™ vaccine at Day 0. The Fluarix™ vaccine was administered as a single dose intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>GSK2604409A Group</title>
            <description>Subjects received one dose of the GSK2604409A vaccine at Day 0. The GSK2604409A vaccine was administered as a single dose intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Titers for Hemagglutination Inhibition (HI) Antibodies Against 4 Strains of Influenza Disease</title>
          <description>Titers are presented as geometric mean titers (GMTs). The reference cut-off value was 1:10. HI antibodies assessed were antibodies against the A/California/7/2009 (H1N1), A/Victoria/210/2009 (H3N2), B/Brisbane/60/2008 (Victoria), and B/Brisbane/3/2007 (Yamagata) flu strains. Subjects receiving the GSK2321138A vaccine were pooled for this outcome measure.</description>
          <population>The analysis was performed on the According-to-Protocol cohort for Immunogenicity, which included all vaccinated and eligible subjects for whom data concerning immunogenicity outcome measures were available, and for whom assay results were available for antibodies against at least 1 study vaccine antigen component after vaccination.</population>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1809"/>
                <count group_id="O2" value="608"/>
                <count group_id="O3" value="534"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H1N1 Strain – D0 (N=1801;605;530)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.7" lower_limit="13.8" upper_limit="15.6"/>
                    <measurement group_id="O2" value="15.6" lower_limit="14.1" upper_limit="17.3"/>
                    <measurement group_id="O3" value="14.4" lower_limit="12.9" upper_limit="16.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H1N1 Strain – D21 (N=1809;608;534)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="201.1" lower_limit="188.1" upper_limit="215.1"/>
                    <measurement group_id="O2" value="218.4" lower_limit="194.2" upper_limit="245.6"/>
                    <measurement group_id="O3" value="213.0" lower_limit="187.6" upper_limit="241.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2 Strain – D0 (N=1801;605;530)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.0" lower_limit="31.8" upper_limit="36.3"/>
                    <measurement group_id="O2" value="38.1" lower_limit="34.1" upper_limit="42.7"/>
                    <measurement group_id="O3" value="35.7" lower_limit="31.6" upper_limit="40.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2 Strain – D21 (N=1809;608;534)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="314.7" lower_limit="296.8" upper_limit="333.6"/>
                    <measurement group_id="O2" value="298.2" lower_limit="268.4" upper_limit="331.3"/>
                    <measurement group_id="O3" value="340.4" lower_limit="304.3" upper_limit="380.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Victoria Strain – D0 (N=1801;605;530)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.8" lower_limit="69.1" upper_limit="78.8"/>
                    <measurement group_id="O2" value="73.6" lower_limit="65.5" upper_limit="82.8"/>
                    <measurement group_id="O3" value="71.7" lower_limit="63.4" upper_limit="81.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Victoria Strain – D21 (N=1809;608;534)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="404.6" lower_limit="386.6" upper_limit="423.4"/>
                    <measurement group_id="O2" value="393.8" lower_limit="362.7" upper_limit="427.6"/>
                    <measurement group_id="O3" value="258.5" lower_limit="234.6" upper_limit="284.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Yamagata Strain – D0 (N=1801;605;530)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101.4" lower_limit="94.5" upper_limit="108.8"/>
                    <measurement group_id="O2" value="100.9" lower_limit="89.3" upper_limit="113.9"/>
                    <measurement group_id="O3" value="99.8" lower_limit="87.7" upper_limit="113.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Yamagata Strain – D21 (N=1809;608;534)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="601.8" lower_limit="573.3" upper_limit="631.6"/>
                    <measurement group_id="O2" value="386.6" lower_limit="351.5" upper_limit="425.3"/>
                    <measurement group_id="O3" value="582.5" lower_limit="534.6" upper_limit="634.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Seroconverted Subjects Against 4 Strains of Influenza Disease</title>
        <description>A seroconverted subject was a vaccinated subject who had either a pre-vaccination hemagglutination inhibition (HI) antibody titer &lt; 1:10 and a post-vaccination titer above or equal (&gt;=) 1:40, or a pre-vaccination HI antibody titer &gt;= 1:10 and at least a 4-fold increase in post-vaccination HI antibody titer. Antibodies assessed were HI antibodies against the A/California/7/2009 (H1N1), A/Victoria/210/2009 (H3N2), B/Brisbane/60/2008 (Victoria), and B/Brisbane/3/2007 (Yamagata) flu strains. Subjects receiving the GSK2321138A vaccine were pooled for this outcome measure.</description>
        <time_frame>At Day 21 (D21)</time_frame>
        <population>The analysis was performed on the According-to-Protocol cohort for Immunogenicity, which included all vaccinated and eligible subjects for whom data concerning immunogenicity outcome measures were available, and for whom assay results were available for antibodies against at least 1 study vaccine antigen component after vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2321138A Group</title>
            <description>Subjects received one dose of the GSK2321138A vaccine, Lot 1, 2 or 3, at Day 0. The GSK2321138A vaccine was administered as a single dose intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Group</title>
            <description>Subjects received one dose of the Fluarix™ vaccine at Day 0. The Fluarix™ vaccine was administered as a single dose intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>GSK2604409A Group</title>
            <description>Subjects received one dose of the GSK2604409A vaccine at Day 0. The GSK2604409A vaccine was administered as a single dose intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Seroconverted Subjects Against 4 Strains of Influenza Disease</title>
          <description>A seroconverted subject was a vaccinated subject who had either a pre-vaccination hemagglutination inhibition (HI) antibody titer &lt; 1:10 and a post-vaccination titer above or equal (&gt;=) 1:40, or a pre-vaccination HI antibody titer &gt;= 1:10 and at least a 4-fold increase in post-vaccination HI antibody titer. Antibodies assessed were HI antibodies against the A/California/7/2009 (H1N1), A/Victoria/210/2009 (H3N2), B/Brisbane/60/2008 (Victoria), and B/Brisbane/3/2007 (Yamagata) flu strains. Subjects receiving the GSK2321138A vaccine were pooled for this outcome measure.</description>
          <population>The analysis was performed on the According-to-Protocol cohort for Immunogenicity, which included all vaccinated and eligible subjects for whom data concerning immunogenicity outcome measures were available, and for whom assay results were available for antibodies against at least 1 study vaccine antigen component after vaccination.</population>
          <units>Subject</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1801"/>
                <count group_id="O2" value="605"/>
                <count group_id="O3" value="530"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H1N1 Strain – D21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1396"/>
                    <measurement group_id="O2" value="467"/>
                    <measurement group_id="O3" value="425"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2 Strain – D21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1287"/>
                    <measurement group_id="O2" value="398"/>
                    <measurement group_id="O3" value="371"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Victoria Strain – D21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1046"/>
                    <measurement group_id="O2" value="335"/>
                    <measurement group_id="O3" value="252"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Yamagata Strain – D21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1112"/>
                    <measurement group_id="O2" value="276"/>
                    <measurement group_id="O3" value="313"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Seropositive Subjects Against 4 Strains of Influenza Disease</title>
        <description>A seropositive subject was a vaccinated subject with hemagglutination inhibition (HI) antibody titer above or equal (&gt;=) the reference cut-off value of 1:10. Antibodies assessed were HI antibodies against the A/California/7/2009 (H1N1), A/Victoria/210/2009 (H3N2), B/Brisbane/60/2008 (Victoria), and B/Brisbane/3/2007 (Yamagata) flu strains. Subjects receiving the GSK2321138A vaccine were pooled for this outcome measure.</description>
        <time_frame>At Day 0 (D0), and at Day 21 (D21)</time_frame>
        <population>The analysis was performed on the According-to-Protocol cohort for Immunogenicity, which included all vaccinated and eligible subjects for whom data concerning immunogenicity outcome measures were available, and for whom assay results were available for antibodies against at least 1 study vaccine antigen component after vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2321138A Group</title>
            <description>Subjects received one dose of the GSK2321138A vaccine, Lot 1, 2 or 3, at Day 0. The GSK2321138A vaccine was administered as a single dose intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Group</title>
            <description>Subjects received one dose of the Fluarix™ vaccine at Day 0. The Fluarix™ vaccine was administered as a single dose intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>GSK2604409A Group</title>
            <description>Subjects received one dose of the GSK2604409A vaccine at Day 0. The GSK2604409A vaccine was administered as a single dose intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Seropositive Subjects Against 4 Strains of Influenza Disease</title>
          <description>A seropositive subject was a vaccinated subject with hemagglutination inhibition (HI) antibody titer above or equal (&gt;=) the reference cut-off value of 1:10. Antibodies assessed were HI antibodies against the A/California/7/2009 (H1N1), A/Victoria/210/2009 (H3N2), B/Brisbane/60/2008 (Victoria), and B/Brisbane/3/2007 (Yamagata) flu strains. Subjects receiving the GSK2321138A vaccine were pooled for this outcome measure.</description>
          <population>The analysis was performed on the According-to-Protocol cohort for Immunogenicity, which included all vaccinated and eligible subjects for whom data concerning immunogenicity outcome measures were available, and for whom assay results were available for antibodies against at least 1 study vaccine antigen component after vaccination.</population>
          <units>Subject</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1809"/>
                <count group_id="O2" value="608"/>
                <count group_id="O3" value="534"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H1N1 Strain – D0 (N=1801;605;530)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="967"/>
                    <measurement group_id="O2" value="352"/>
                    <measurement group_id="O3" value="291"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H1N1 Strain – D21 (N=1809;608;534)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1738"/>
                    <measurement group_id="O2" value="586"/>
                    <measurement group_id="O3" value="514"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2 Strain – D0 (N=1801;605;530)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1416"/>
                    <measurement group_id="O2" value="488"/>
                    <measurement group_id="O3" value="425"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2 Strain – D21 (N=1809;608;534)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1783"/>
                    <measurement group_id="O2" value="594"/>
                    <measurement group_id="O3" value="528"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Victoria Strain – D0 (N=1801;605;530)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1541"/>
                    <measurement group_id="O2" value="511"/>
                    <measurement group_id="O3" value="452"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Victoria Strain – D21 (N=1809;608;534)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1795"/>
                    <measurement group_id="O2" value="601"/>
                    <measurement group_id="O3" value="518"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Yamagata Strain – D0 (N=1801;605;530)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1554"/>
                    <measurement group_id="O2" value="525"/>
                    <measurement group_id="O3" value="457"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Yamagata Strain – D21 (N=1809;608;534)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1794"/>
                    <measurement group_id="O2" value="597"/>
                    <measurement group_id="O3" value="532"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Seroprotected Subjects Against 4 Strains of Influenza Disease</title>
        <description>A seroprotected subject was a vaccinated subject who had hemagglutination inhibition (HI) antibody titer above or equal (&gt;=) 1:40. Antibodies assessed were HI antibodies against the A/California/7/2009 (H1N1), A/Victoria/210/2009 (H3N2), B/Brisbane/60/2008 (Victoria), and B/Brisbane/3/2007 (Yamagata) flu strains. Subjects receiving the GSK2321138A vaccine were pooled for this outcome measure.</description>
        <time_frame>At Day 0 (D0), and at Day 21 (D21)</time_frame>
        <population>The analysis was performed on the According-to-Protocol cohort for Immunogenicity, which included all vaccinated and eligible subjects for whom data concerning immunogenicity outcome measures were available, and for whom assay results were available for antibodies against at least 1 study vaccine antigen component after vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2321138A Group</title>
            <description>Subjects received one dose of the GSK2321138A vaccine, Lot 1, 2 or 3, at Day 0. The GSK2321138A vaccine was administered as a single dose intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Group</title>
            <description>Subjects received one dose of the Fluarix™ vaccine at Day 0. The Fluarix™ vaccine was administered as a single dose intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>GSK2604409A Group</title>
            <description>Subjects received one dose of the GSK2604409A vaccine at Day 0. The GSK2604409A vaccine was administered as a single dose intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Seroprotected Subjects Against 4 Strains of Influenza Disease</title>
          <description>A seroprotected subject was a vaccinated subject who had hemagglutination inhibition (HI) antibody titer above or equal (&gt;=) 1:40. Antibodies assessed were HI antibodies against the A/California/7/2009 (H1N1), A/Victoria/210/2009 (H3N2), B/Brisbane/60/2008 (Victoria), and B/Brisbane/3/2007 (Yamagata) flu strains. Subjects receiving the GSK2321138A vaccine were pooled for this outcome measure.</description>
          <population>The analysis was performed on the According-to-Protocol cohort for Immunogenicity, which included all vaccinated and eligible subjects for whom data concerning immunogenicity outcome measures were available, and for whom assay results were available for antibodies against at least 1 study vaccine antigen component after vaccination.</population>
          <units>Subject</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1809"/>
                <count group_id="O2" value="608"/>
                <count group_id="O3" value="534"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H1N1 Strain – D0 (N=1801;605;530)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="514"/>
                    <measurement group_id="O2" value="167"/>
                    <measurement group_id="O3" value="139"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H1N1 Strain – D21 (N=1809;608;534)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1651"/>
                    <measurement group_id="O2" value="558"/>
                    <measurement group_id="O3" value="495"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2 Strain – D0 (N=1801;605;530)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="965"/>
                    <measurement group_id="O2" value="353"/>
                    <measurement group_id="O3" value="285"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2 Strain – D21 (N=1809;608;534)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1751"/>
                    <measurement group_id="O2" value="583"/>
                    <measurement group_id="O3" value="517"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Victoria Strain – D0 (N=1801;605;530)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1423"/>
                    <measurement group_id="O2" value="477"/>
                    <measurement group_id="O3" value="412"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Victoria Strain – D21 (N=1809;608;534)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1788"/>
                    <measurement group_id="O2" value="599"/>
                    <measurement group_id="O3" value="513"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Yamagata Strain – D0 (N=1801;605;530)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1494"/>
                    <measurement group_id="O2" value="497"/>
                    <measurement group_id="O3" value="441"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Yamagata Strain – D21 (N=1809;608;534)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1792"/>
                    <measurement group_id="O2" value="595"/>
                    <measurement group_id="O3" value="532"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Increase in Hemagglutination Inhibition Antibodies Against 4 Strains of Influenza Disease</title>
        <description>Increase in hemagglutination inhibition (HI) antibodies is presented in terms of mean geometric increase (MGI), defined as the geometric mean of the within subject ratios of the post-vaccination reciprocal HI titer to the Day 0 reciprocal HI titer , expressed using “fold increase” as unit . Antibodies assessed were HI antibodies against the A/California/7/2009 (H1N1), A/Victoria/210/2009 (H3N2), B/Brisbane/60/2008 (Victoria), and B/Brisbane/3/2007 (Yamagata) flu strains. Subjects receiving the GSK2321138A vaccine were pooled for this outcome measure.</description>
        <time_frame>At Day 21 (D21)</time_frame>
        <population>The analysis was performed on the According-to-Protocol cohort for Immunogenicity, which included all vaccinated and eligible subjects for whom data concerning immunogenicity outcome measures were available, and for whom assay results were available for antibodies against at least 1 study vaccine antigen component after vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2321138A Group</title>
            <description>Subjects received one dose of the GSK2321138A vaccine, Lot 1, 2 or 3, at Day 0. The GSK2321138A vaccine was administered as a single dose intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Group</title>
            <description>Subjects received one dose of the Fluarix™ vaccine at Day 0. The Fluarix™ vaccine was administered as a single dose intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>GSK2604409A Group</title>
            <description>Subjects received one dose of the GSK2604409A vaccine at Day 0. The GSK2604409A vaccine was administered as a single dose intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Increase in Hemagglutination Inhibition Antibodies Against 4 Strains of Influenza Disease</title>
          <description>Increase in hemagglutination inhibition (HI) antibodies is presented in terms of mean geometric increase (MGI), defined as the geometric mean of the within subject ratios of the post-vaccination reciprocal HI titer to the Day 0 reciprocal HI titer , expressed using “fold increase” as unit . Antibodies assessed were HI antibodies against the A/California/7/2009 (H1N1), A/Victoria/210/2009 (H3N2), B/Brisbane/60/2008 (Victoria), and B/Brisbane/3/2007 (Yamagata) flu strains. Subjects receiving the GSK2321138A vaccine were pooled for this outcome measure.</description>
          <population>The analysis was performed on the According-to-Protocol cohort for Immunogenicity, which included all vaccinated and eligible subjects for whom data concerning immunogenicity outcome measures were available, and for whom assay results were available for antibodies against at least 1 study vaccine antigen component after vaccination.</population>
          <units>fold increase</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1801"/>
                <count group_id="O2" value="605"/>
                <count group_id="O3" value="530"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H1N1 Strain – D21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.69" lower_limit="12.70" upper_limit="14.76"/>
                    <measurement group_id="O2" value="13.92" lower_limit="12.23" upper_limit="15.84"/>
                    <measurement group_id="O3" value="14.88" lower_limit="12.91" upper_limit="17.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2 Strain – D21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.28" lower_limit="8.64" upper_limit="9.96"/>
                    <measurement group_id="O2" value="7.84" lower_limit="6.93" upper_limit="8.88"/>
                    <measurement group_id="O3" value="9.52" lower_limit="8.33" upper_limit="10.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Victoria Strain – D21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.48" lower_limit="5.12" upper_limit="5.85"/>
                    <measurement group_id="O2" value="5.37" lower_limit="4.75" upper_limit="6.06"/>
                    <measurement group_id="O3" value="3.60" lower_limit="3.25" upper_limit="3.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Yamagata Strain – D21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.93" lower_limit="5.53" upper_limit="6.36"/>
                    <measurement group_id="O2" value="3.84" lower_limit="3.42" upper_limit="4.30"/>
                    <measurement group_id="O3" value="5.84" lower_limit="5.13" upper_limit="6.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Any and Grade 3 Solicited Local Symptoms.</title>
        <description>Assessed solicited local symptoms post vaccination were pain, redness and swelling at the injection site. Any = occurrence of a symptom regardless of intensity. Grade 3 pain = significant pain at rest/ that prevented normal every day activities. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site.</description>
        <time_frame>Within the 7-day (Days 0-6) follow-up period after vaccination</time_frame>
        <population>The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects, solely on subjects with available results.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2321138A Lot 1 Group</title>
            <description>Subjects received one dose of the GSK2321138A vaccine, Lot 1, at Day 0. The GSK2321138A vaccine was administered as a single dose intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK2321138A Lot 2 Group</title>
            <description>Subjects received one dose of the GSK2321138A vaccine, Lot 2, at Day 0. The GSK2321138A vaccine was administered as a single dose intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>GSK2321138A Lot 3 Group</title>
            <description>Subjects received one dose of the GSK2321138A vaccine, Lot 3, at Day 0. The GSK2321138A vaccine was administered as a single dose intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Fluarix Group</title>
            <description>Subjects received one dose of the Fluarix™ vaccine at Day 0. The Fluarix™ vaccine was administered as a single dose intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>GSK2604409A Group</title>
            <description>Subjects received one dose of the GSK2604409A vaccine at Day 0. The GSK2604409A vaccine was administered as a single dose intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Any and Grade 3 Solicited Local Symptoms.</title>
          <description>Assessed solicited local symptoms post vaccination were pain, redness and swelling at the injection site. Any = occurrence of a symptom regardless of intensity. Grade 3 pain = significant pain at rest/ that prevented normal every day activities. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site.</description>
          <population>The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects, solely on subjects with available results.</population>
          <units>Subject</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1008"/>
                <count group_id="O2" value="1003"/>
                <count group_id="O3" value="1004"/>
                <count group_id="O4" value="1003"/>
                <count group_id="O5" value="607"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="377"/>
                    <measurement group_id="O2" value="362"/>
                    <measurement group_id="O3" value="357"/>
                    <measurement group_id="O4" value="369"/>
                    <measurement group_id="O5" value="190"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="12"/>
                    <measurement group_id="O5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Redness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="22"/>
                    <measurement group_id="O4" value="17"/>
                    <measurement group_id="O5" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Redness (&gt;= 100 mm)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="21"/>
                    <measurement group_id="O5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Swelling (&gt;= 100 mm)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Days With Solicited Local Symptoms</title>
        <description>Assessed solicited local symptoms post vaccination were pain, redness and swelling at the injection site.</description>
        <time_frame>Within the 7-day (Days 0-6) follow-up period after vaccination</time_frame>
        <population>The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects, solely on subjects with available results.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2321138A Lot 1 Group</title>
            <description>Subjects received one dose of the GSK2321138A vaccine, Lot 1, at Day 0. The GSK2321138A vaccine was administered as a single dose intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK2321138A Lot 2 Group</title>
            <description>Subjects received one dose of the GSK2321138A vaccine, Lot 2, at Day 0. The GSK2321138A vaccine was administered as a single dose intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>GSK2321138A Lot 3 Group</title>
            <description>Subjects received one dose of the GSK2321138A vaccine, Lot 3, at Day 0. The GSK2321138A vaccine was administered as a single dose intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Fluarix Group</title>
            <description>Subjects received one dose of the Fluarix™ vaccine at Day 0. The Fluarix™ vaccine was administered as a single dose intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>GSK2604409A Group</title>
            <description>Subjects received one dose of the GSK2604409A vaccine at Day 0. The GSK2604409A vaccine was administered as a single dose intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Days With Solicited Local Symptoms</title>
          <description>Assessed solicited local symptoms post vaccination were pain, redness and swelling at the injection site.</description>
          <population>The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects, solely on subjects with available results.</population>
          <units>Day</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="377"/>
                <count group_id="O2" value="362"/>
                <count group_id="O3" value="357"/>
                <count group_id="O4" value="369"/>
                <count group_id="O5" value="190"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pain (N=377;362;357;369;190)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="1.0" upper_limit="2.0"/>
                    <measurement group_id="O2" value="2.0" lower_limit="1.0" upper_limit="3.0"/>
                    <measurement group_id="O3" value="2.0" lower_limit="1.0" upper_limit="2.0"/>
                    <measurement group_id="O4" value="2.0" lower_limit="1.0" upper_limit="3.0"/>
                    <measurement group_id="O5" value="2.0" lower_limit="1.0" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness (N=24;12;22;17;12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="1.0" upper_limit="2.5"/>
                    <measurement group_id="O2" value="2.5" lower_limit="1.5" upper_limit="4.5"/>
                    <measurement group_id="O3" value="2.0" lower_limit="1.0" upper_limit="4.0"/>
                    <measurement group_id="O4" value="1.0" lower_limit="1.0" upper_limit="2.0"/>
                    <measurement group_id="O5" value="1.0" lower_limit="1.0" upper_limit="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling (N=26;20;16;21;8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="1.0" upper_limit="3.0"/>
                    <measurement group_id="O2" value="2.0" lower_limit="1.0" upper_limit="3.0"/>
                    <measurement group_id="O3" value="2.0" lower_limit="1.5" upper_limit="3.0"/>
                    <measurement group_id="O4" value="2.0" lower_limit="1.0" upper_limit="3.0"/>
                    <measurement group_id="O5" value="2.5" lower_limit="1.0" upper_limit="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms</title>
        <description>Assessed solicited general symptoms post vaccination were fatigue, gastrointestinal symptoms (Gastr.), headache, joint pain at other location (Joint Pain), muscle aches, shivering, and temperature [axillary temperature above or equal to (&gt;=) 37.5 degrees Celsius (°C)]. Any = occurrence of a symptom regardless of intensity or relationship to vaccination. Grade 3 = symptom which prevented normal every day activities. Grade 3 temperature = axillary temperature &gt; 39°C. Related = symptom assessed as causally related to study vaccination.</description>
        <time_frame>Within the 7-day (Days 0-6) follow-up period after vaccination</time_frame>
        <population>The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects, solely on subjects with available results.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2321138A Lot 1 Group</title>
            <description>Subjects received one dose of the GSK2321138A vaccine, Lot 1, at Day 0. The GSK2321138A vaccine was administered as a single dose intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK2321138A Lot 2 Group</title>
            <description>Subjects received one dose of the GSK2321138A vaccine, Lot 2, at Day 0. The GSK2321138A vaccine was administered as a single dose intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>GSK2321138A Lot 3 Group</title>
            <description>Subjects received one dose of the GSK2321138A vaccine, Lot 3, at Day 0. The GSK2321138A vaccine was administered as a single dose intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Fluarix Group</title>
            <description>Subjects received one dose of the Fluarix™ vaccine at Day 0. The Fluarix™ vaccine was administered as a single dose intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>GSK2604409A Group</title>
            <description>Subjects received one dose of the GSK2604409A vaccine at Day 0. The GSK2604409A vaccine was administered as a single dose intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms</title>
          <description>Assessed solicited general symptoms post vaccination were fatigue, gastrointestinal symptoms (Gastr.), headache, joint pain at other location (Joint Pain), muscle aches, shivering, and temperature [axillary temperature above or equal to (&gt;=) 37.5 degrees Celsius (°C)]. Any = occurrence of a symptom regardless of intensity or relationship to vaccination. Grade 3 = symptom which prevented normal every day activities. Grade 3 temperature = axillary temperature &gt; 39°C. Related = symptom assessed as causally related to study vaccination.</description>
          <population>The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects, solely on subjects with available results.</population>
          <units>Subject</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1008"/>
                <count group_id="O2" value="1001"/>
                <count group_id="O3" value="1002"/>
                <count group_id="O4" value="1003"/>
                <count group_id="O5" value="607"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="152"/>
                    <measurement group_id="O2" value="154"/>
                    <measurement group_id="O3" value="171"/>
                    <measurement group_id="O4" value="185"/>
                    <measurement group_id="O5" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109"/>
                    <measurement group_id="O2" value="107"/>
                    <measurement group_id="O3" value="118"/>
                    <measurement group_id="O4" value="132"/>
                    <measurement group_id="O5" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Gastr.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64"/>
                    <measurement group_id="O2" value="63"/>
                    <measurement group_id="O3" value="70"/>
                    <measurement group_id="O4" value="65"/>
                    <measurement group_id="O5" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Gastr.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Gastr.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="34"/>
                    <measurement group_id="O3" value="38"/>
                    <measurement group_id="O4" value="35"/>
                    <measurement group_id="O5" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="163"/>
                    <measurement group_id="O2" value="162"/>
                    <measurement group_id="O3" value="155"/>
                    <measurement group_id="O4" value="164"/>
                    <measurement group_id="O5" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87"/>
                    <measurement group_id="O2" value="92"/>
                    <measurement group_id="O3" value="98"/>
                    <measurement group_id="O4" value="97"/>
                    <measurement group_id="O5" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Joint Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96"/>
                    <measurement group_id="O2" value="84"/>
                    <measurement group_id="O3" value="74"/>
                    <measurement group_id="O4" value="104"/>
                    <measurement group_id="O5" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Joint Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Joint Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67"/>
                    <measurement group_id="O2" value="54"/>
                    <measurement group_id="O3" value="51"/>
                    <measurement group_id="O4" value="61"/>
                    <measurement group_id="O5" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Muscle Aches</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="165"/>
                    <measurement group_id="O2" value="172"/>
                    <measurement group_id="O3" value="156"/>
                    <measurement group_id="O4" value="195"/>
                    <measurement group_id="O5" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Muscle Aches</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Muscle Aches</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="117"/>
                    <measurement group_id="O2" value="130"/>
                    <measurement group_id="O3" value="109"/>
                    <measurement group_id="O4" value="137"/>
                    <measurement group_id="O5" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Shivering</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="32"/>
                    <measurement group_id="O3" value="48"/>
                    <measurement group_id="O4" value="50"/>
                    <measurement group_id="O5" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Shivering</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Shivering</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="32"/>
                    <measurement group_id="O4" value="30"/>
                    <measurement group_id="O5" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Temperature ( &gt;=37.5°C)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="12"/>
                    <measurement group_id="O5" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Temperature (&gt;39.0°C)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Temperature</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Days With Solicited General Symptoms</title>
        <description>Assessed solicited general symptoms post vaccination were fatigue, gastrointestinal symptoms (Gastr.), headache, joint pain at other location (Joint Pain), muscle aches, shivering, and temperature [defined as axillary temperature above or equal to (&gt; =) 37.5 degrees Celsius (°C)].</description>
        <time_frame>Within the 7-day (Days 0-6) follow-up period after vaccination</time_frame>
        <population>The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects, solely on subjects with available results.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2321138A Lot 1 Group</title>
            <description>Subjects received one dose of the GSK2321138A vaccine, Lot 1, at Day 0. The GSK2321138A vaccine was administered as a single dose intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK2321138A Lot 2 Group</title>
            <description>Subjects received one dose of the GSK2321138A vaccine, Lot 2, at Day 0. The GSK2321138A vaccine was administered as a single dose intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>GSK2321138A Lot 3 Group</title>
            <description>Subjects received one dose of the GSK2321138A vaccine, Lot 3, at Day 0. The GSK2321138A vaccine was administered as a single dose intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Fluarix Group</title>
            <description>Subjects received one dose of the Fluarix™ vaccine at Day 0. The Fluarix™ vaccine was administered as a single dose intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>GSK2604409A Group</title>
            <description>Subjects received one dose of the GSK2604409A vaccine at Day 0. The GSK2604409A vaccine was administered as a single dose intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Days With Solicited General Symptoms</title>
          <description>Assessed solicited general symptoms post vaccination were fatigue, gastrointestinal symptoms (Gastr.), headache, joint pain at other location (Joint Pain), muscle aches, shivering, and temperature [defined as axillary temperature above or equal to (&gt; =) 37.5 degrees Celsius (°C)].</description>
          <population>The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects, solely on subjects with available results.</population>
          <units>Day</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="165"/>
                <count group_id="O2" value="172"/>
                <count group_id="O3" value="156"/>
                <count group_id="O4" value="195"/>
                <count group_id="O5" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fatigue (N=152;154;171;185;90)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="1.0" upper_limit="3.0"/>
                    <measurement group_id="O2" value="2.0" lower_limit="1.0" upper_limit="3.0"/>
                    <measurement group_id="O3" value="2.0" lower_limit="1.0" upper_limit="3.0"/>
                    <measurement group_id="O4" value="2.0" lower_limit="1.0" upper_limit="3.0"/>
                    <measurement group_id="O5" value="2.0" lower_limit="1.0" upper_limit="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gastr. (N=64;63;70;65;36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="1.0" upper_limit="3.0"/>
                    <measurement group_id="O2" value="2.0" lower_limit="1.0" upper_limit="3.0"/>
                    <measurement group_id="O3" value="2.0" lower_limit="1.0" upper_limit="3.0"/>
                    <measurement group_id="O4" value="2.0" lower_limit="1.0" upper_limit="3.0"/>
                    <measurement group_id="O5" value="2.0" lower_limit="1.0" upper_limit="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache (N=163;162;155;16;80))</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="1.0" upper_limit="3.0"/>
                    <measurement group_id="O2" value="2.0" lower_limit="1.0" upper_limit="3.0"/>
                    <measurement group_id="O3" value="2.0" lower_limit="1.0" upper_limit="2.0"/>
                    <measurement group_id="O4" value="2.0" lower_limit="1.0" upper_limit="2.0"/>
                    <measurement group_id="O5" value="1.0" lower_limit="1.0" upper_limit="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Joint Pain (N=96;84;74;104;57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="1.0" upper_limit="4.0"/>
                    <measurement group_id="O2" value="2.0" lower_limit="1.0" upper_limit="4.0"/>
                    <measurement group_id="O3" value="2.0" lower_limit="1.0" upper_limit="4.0"/>
                    <measurement group_id="O4" value="2.0" lower_limit="1.0" upper_limit="3.0"/>
                    <measurement group_id="O5" value="2.0" lower_limit="1.0" upper_limit="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Muscle Aches (N=165;172;156;195;98)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="1.0" upper_limit="3.0"/>
                    <measurement group_id="O2" value="2.0" lower_limit="1.0" upper_limit="3.0"/>
                    <measurement group_id="O3" value="2.0" lower_limit="1.0" upper_limit="3.0"/>
                    <measurement group_id="O4" value="2.0" lower_limit="1.0" upper_limit="3.0"/>
                    <measurement group_id="O5" value="2.0" lower_limit="1.0" upper_limit="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Shivering (N=45;32;48;50;26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="1.0" upper_limit="2.0"/>
                    <measurement group_id="O2" value="2.0" lower_limit="1.0" upper_limit="2.0"/>
                    <measurement group_id="O3" value="2.0" lower_limit="1.0" upper_limit="3.0"/>
                    <measurement group_id="O4" value="1.0" lower_limit="1.0" upper_limit="2.0"/>
                    <measurement group_id="O5" value="1.5" lower_limit="1.0" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Temperature (N=19;21;8;12;9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="1.0" upper_limit="2.0"/>
                    <measurement group_id="O2" value="1.0" lower_limit="1.0" upper_limit="3.0"/>
                    <measurement group_id="O3" value="1.0" lower_limit="1.0" upper_limit="1.0"/>
                    <measurement group_id="O4" value="1.0" lower_limit="1.0" upper_limit="2.0"/>
                    <measurement group_id="O5" value="2.0" lower_limit="1.0" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)</title>
        <description>Unsolicited AEs cover any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any unsolicited AE = any unsolicited AE regardless of intensity or relationship to vaccination. Grade 3 unsolicited AE = unsolicited AE that prevented normal everyday activity Related unsolicited AE = unsolicited AE assessed by the investigator as related to the vaccination.</description>
        <time_frame>Within the 21-day (Days 0-20) follow-up period after vaccination</time_frame>
        <population>The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2321138A Lot 1 Group</title>
            <description>Subjects received one dose of the GSK2321138A vaccine, Lot 1, at Day 0. The GSK2321138A vaccine was administered as a single dose intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK2321138A Lot 2 Group</title>
            <description>Subjects received one dose of the GSK2321138A vaccine, Lot 2, at Day 0. The GSK2321138A vaccine was administered as a single dose intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>GSK2321138A Lot 3 Group</title>
            <description>Subjects received one dose of the GSK2321138A vaccine, Lot 3, at Day 0. The GSK2321138A vaccine was administered as a single dose intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Fluarix Group</title>
            <description>Subjects received one dose of the Fluarix™ vaccine at Day 0. The Fluarix™ vaccine was administered as a single dose intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>GSK2604409A Group</title>
            <description>Subjects received one dose of the GSK2604409A vaccine at Day 0. The GSK2604409A vaccine was administered as a single dose intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)</title>
          <description>Unsolicited AEs cover any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any unsolicited AE = any unsolicited AE regardless of intensity or relationship to vaccination. Grade 3 unsolicited AE = unsolicited AE that prevented normal everyday activity Related unsolicited AE = unsolicited AE assessed by the investigator as related to the vaccination.</description>
          <population>The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects.</population>
          <units>Subject</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1012"/>
                <count group_id="O2" value="1013"/>
                <count group_id="O3" value="1011"/>
                <count group_id="O4" value="1010"/>
                <count group_id="O5" value="610"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Unsolicited AE(s)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="125"/>
                    <measurement group_id="O2" value="120"/>
                    <measurement group_id="O3" value="134"/>
                    <measurement group_id="O4" value="138"/>
                    <measurement group_id="O5" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Unsolicited AE(s)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Unsolicited AE(s)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="27"/>
                    <measurement group_id="O4" value="26"/>
                    <measurement group_id="O5" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Any and Related Adverse Events With Medically-attended Events (MAEs)</title>
        <description>Medically-attended events (MAEs) refer to non-serious and serious events leading to an otherwise unscheduled visit to or from medical personnel for any reason, including emergency room visits. If a MAE was leading to hospitalisation (or met any other serious adverse event criterion), it was reported as serious adverse event. Related MAE = MAE assessed by the investigator as related to the vaccination. Subjects receiving the GSK2321138A vaccine were pooled for this outcome measure.</description>
        <time_frame>From the beginning of the study (Day 0) to study end (Day 180)</time_frame>
        <population>The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2321138A Group</title>
            <description>Subjects received one dose of the GSK2321138A vaccine, Lot 1, 2 or 3, at Day 0. The GSK2321138A vaccine was administered as a single dose intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Group</title>
            <description>Subjects received one dose of the Fluarix™ vaccine at Day 0. The Fluarix™ vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>GSK2604409A Group</title>
            <description>Subjects received one dose of the GSK2604409A vaccine at Day 0. The GSK2604409A vaccine was administered as a single dose intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Any and Related Adverse Events With Medically-attended Events (MAEs)</title>
          <description>Medically-attended events (MAEs) refer to non-serious and serious events leading to an otherwise unscheduled visit to or from medical personnel for any reason, including emergency room visits. If a MAE was leading to hospitalisation (or met any other serious adverse event criterion), it was reported as serious adverse event. Related MAE = MAE assessed by the investigator as related to the vaccination. Subjects receiving the GSK2321138A vaccine were pooled for this outcome measure.</description>
          <population>The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects.</population>
          <units>Subject</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3036"/>
                <count group_id="O2" value="1010"/>
                <count group_id="O3" value="610"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any MAE(s)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="688"/>
                    <measurement group_id="O2" value="216"/>
                    <measurement group_id="O3" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related MAE(s)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Any and Related Potential Immune-mediated Diseases (pIMDs)</title>
        <description>Potential immune-mediated diseases (pIMDs) are a subset of adverse events that include both clearly autoimmune diseases and also other inflammatory and/or neurologic disorders which may or may not have an autoimmune etiology. Related pIMD = pIMD assessed by the investigator as related to the vaccination. Subjects receiving the GSK2321138A vaccine were pooled for this outcome measure.</description>
        <time_frame>From the beginning of the study (Day 0) to study end (Day 180)</time_frame>
        <population>The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2321138A Group</title>
            <description>Subjects received one dose of the GSK2321138A vaccine, Lot 1, 2 or 3, at Day 0. The GSK2321138A vaccine was administered as a single dose intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Group</title>
            <description>Subjects received one dose of the Fluarix™ vaccine at Day 0. The Fluarix™ vaccine was administered as a single dose intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>GSK2604409A Group</title>
            <description>Subjects received one dose of the GSK2604409A vaccine at Day 0. The GSK2604409A vaccine was administered as a single dose intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Any and Related Potential Immune-mediated Diseases (pIMDs)</title>
          <description>Potential immune-mediated diseases (pIMDs) are a subset of adverse events that include both clearly autoimmune diseases and also other inflammatory and/or neurologic disorders which may or may not have an autoimmune etiology. Related pIMD = pIMD assessed by the investigator as related to the vaccination. Subjects receiving the GSK2321138A vaccine were pooled for this outcome measure.</description>
          <population>The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects.</population>
          <units>Subject</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3036"/>
                <count group_id="O2" value="1010"/>
                <count group_id="O3" value="610"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any pIMD(s)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related pIMD(s)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Any and Related Serious Adverse Events (SAEs)</title>
        <description>Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject. Any SAE = any SAE regardless of intensity or relationship to vaccination. Related SAE = SAE assessed by the investigator as related to the vaccination.</description>
        <time_frame>From the beginning of the study (Day 0) to study end (Day 180)</time_frame>
        <population>The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2321138A Lot 1 Group</title>
            <description>Subjects received one dose of the GSK2321138A vaccine, Lot 1, at Day 0. The GSK2321138A vaccine was administered as a single dose intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK2321138A Lot 2 Group</title>
            <description>Subjects received one dose of the GSK2321138A vaccine, Lot 2, at Day 0. The GSK2321138A vaccine was administered as a single dose intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>GSK2321138A Lot 3 Group</title>
            <description>Subjects received one dose of the GSK2321138A vaccine, Lot 3, at Day 0. The GSK2321138A vaccine was administered as a single dose intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Fluarix Group</title>
            <description>Subjects received one dose of the Fluarix™ vaccine at Day 0. The Fluarix™ vaccine was administered as a single dose intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>GSK2604409A Group</title>
            <description>Subjects received one dose of the GSK2604409A vaccine at Day 0. The GSK2604409A vaccine was administered as a single dose intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Any and Related Serious Adverse Events (SAEs)</title>
          <description>Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject. Any SAE = any SAE regardless of intensity or relationship to vaccination. Related SAE = SAE assessed by the investigator as related to the vaccination.</description>
          <population>The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects.</population>
          <units>Subject</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1012"/>
                <count group_id="O2" value="1013"/>
                <count group_id="O3" value="1011"/>
                <count group_id="O4" value="1010"/>
                <count group_id="O5" value="610"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any SAE(s)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="22"/>
                    <measurement group_id="O4" value="26"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related SAE(s)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Solicited symptoms: Within the 7-day (Days 0-6) follow-up period after vaccination. Unsolicited adverse events: Within the 21-day (Days 0-20) follow-up period after vaccination. Serious adverse events: Throughout the study period (Days 0 to 180)</time_frame>
      <desc>Analysis for unsolicited AEs and SAEs was performed on all vaccinated subjects, and analysis for solicited symptoms was performed solely on vaccinated subjects for whom results were available.</desc>
      <group_list>
        <group group_id="E1">
          <title>GSK2321138A Lot 1 Group</title>
          <description>Subjects received one dose of the GSK2321138A vaccine, Lot 1, at Day 0. The GSK2321138A vaccine was administered as a single dose intramuscularly in the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="E2">
          <title>GSK2321138A Lot 2 Group</title>
          <description>Subjects received one dose of the GSK2321138A vaccine, Lot 2, at Day 0. The GSK2321138A vaccine was administered as a single dose intramuscularly in the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="E3">
          <title>GSK2321138A Lot 3 Group</title>
          <description>Subjects received one dose of the GSK2321138A vaccine, Lot 3, at Day 0. The GSK2321138A vaccine was administered as a single dose intramuscularly in the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="E4">
          <title>Fluarix Group</title>
          <description>Subjects received one dose of the 1 dose of the Fluarix™ vaccine at Day 0. The Fluarix™ vaccine was administered as a single dose intramuscularly in the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="E5">
          <title>GSK2604409A Group</title>
          <description>Subjects received one dose of the GSK2604409A vaccine at Day 0. The GSK2604409A vaccine was administered as a single dose intramuscularly in the deltoid region of the non-dominant arm.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="1012"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="1013"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="1011"/>
                <counts group_id="E4" subjects_affected="26" subjects_at_risk="1010"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="610"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1012"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1013"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1011"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1010"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="610"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1012"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1013"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1011"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1010"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="610"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis coronary artery</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1012"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1013"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1011"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1010"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="610"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1012"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1013"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1011"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1010"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="610"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1012"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1013"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1011"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1010"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="610"/>
              </event>
              <event>
                <sub_title>Cardiac disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1012"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1013"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1011"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1010"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="610"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1012"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1013"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1011"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1010"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="610"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1012"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1013"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1011"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1010"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="610"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1012"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1013"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1011"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1010"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="610"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1012"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1013"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1011"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1010"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="610"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1012"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1013"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1011"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1010"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="610"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1012"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1013"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1011"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1010"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="610"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1012"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1013"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1011"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1010"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="610"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1012"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1013"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1011"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1010"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="610"/>
              </event>
              <event>
                <sub_title>Vestibular disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1012"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1013"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1011"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1010"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="610"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Diplopia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1012"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1013"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1011"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1010"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="610"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1012"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1013"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1011"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1010"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="610"/>
              </event>
              <event>
                <sub_title>Acute abdomen</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1012"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1013"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1011"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1010"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="610"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1012"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1013"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1011"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1010"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="610"/>
              </event>
              <event>
                <sub_title>Gastric ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1012"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1013"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1011"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1010"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="610"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1012"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1013"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1011"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1010"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="610"/>
              </event>
              <event>
                <sub_title>Intestinal infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1012"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1013"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1011"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1010"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="610"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1012"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1013"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1011"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1010"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="610"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1012"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1013"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1011"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1010"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="610"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1012"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1013"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1011"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1010"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="610"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1012"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1013"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1011"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1010"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="610"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1012"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1013"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1011"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1010"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="610"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1012"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1013"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1011"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1010"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="610"/>
              </event>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1012"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1013"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1011"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1010"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="610"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1012"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1013"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1011"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1010"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="610"/>
              </event>
              <event>
                <sub_title>Central nervous system infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1012"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1013"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1011"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1010"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="610"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1012"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1013"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1011"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1010"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="610"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1012"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1013"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1011"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1010"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="610"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1012"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1013"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1011"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1010"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="610"/>
              </event>
              <event>
                <sub_title>Groin abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1012"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1013"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1011"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1010"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="610"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1012"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1013"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1011"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1010"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="610"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1012"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1013"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1011"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1010"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="610"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1012"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1013"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1011"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1010"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="610"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1012"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1013"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1011"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1010"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="610"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1012"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1013"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1011"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1010"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="610"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1012"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1013"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1011"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1010"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="610"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1012"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1013"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1011"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1010"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="610"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1012"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1013"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1011"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1010"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="610"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1012"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1013"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1011"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1010"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="610"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1012"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1013"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1011"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1010"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="610"/>
              </event>
              <event>
                <sub_title>Ligament rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1012"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1013"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1011"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1010"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="610"/>
              </event>
              <event>
                <sub_title>Lumbar vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1012"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1013"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1011"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1010"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="610"/>
              </event>
              <event>
                <sub_title>Pelvic fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1012"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1013"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1011"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1010"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="610"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1012"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1013"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1011"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1010"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="610"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1012"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1013"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1011"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1010"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="610"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Ammonia increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1012"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1013"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1011"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1010"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="610"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1012"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1013"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1011"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1010"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="610"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1012"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1013"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1011"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1010"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="610"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1012"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1013"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1011"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1010"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="610"/>
              </event>
              <event>
                <sub_title>Intervertebral disc disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1012"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1013"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1011"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1010"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="610"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1012"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1013"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1011"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1010"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="610"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1012"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1013"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1011"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1010"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="610"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1012"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1013"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1011"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1010"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="610"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1012"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1013"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1011"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1010"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="610"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1012"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1013"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1011"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1010"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="610"/>
              </event>
              <event>
                <sub_title>Gastric adenoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1012"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1013"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1011"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1010"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="610"/>
              </event>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1012"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1013"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1011"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1010"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="610"/>
              </event>
              <event>
                <sub_title>Hepatic neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1012"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1013"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1011"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1010"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="610"/>
              </event>
              <event>
                <sub_title>Rectal cancer (</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1012"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1013"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1011"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1010"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="610"/>
              </event>
              <event>
                <sub_title>Renal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1012"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1013"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1011"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1010"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="610"/>
              </event>
              <event>
                <sub_title>Small cell lung cancer stage unspecified</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1012"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1013"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1011"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1010"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="610"/>
              </event>
              <event>
                <sub_title>Thyroid cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1012"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1013"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1011"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1010"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="610"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1012"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1013"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1011"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1010"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="610"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1012"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1013"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1011"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1010"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="610"/>
              </event>
              <event>
                <sub_title>Coma hepatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1012"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1013"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1011"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1010"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="610"/>
              </event>
              <event>
                <sub_title>Depressed level of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1012"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1013"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1011"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1010"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="610"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1012"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1013"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1011"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1010"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="610"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1012"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1013"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1011"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1010"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="610"/>
              </event>
              <event>
                <sub_title>Intracranial aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1012"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1013"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1011"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1010"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="610"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1012"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1013"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1011"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1010"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="610"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1012"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1013"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1011"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1010"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="610"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1012"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1013"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1011"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1010"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="610"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1012"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1013"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1011"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1010"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="610"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1012"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1013"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1011"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1010"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="610"/>
              </event>
              <event>
                <sub_title>Ureteric stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1012"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1013"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1011"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1010"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="610"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1012"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1013"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1011"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1010"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="610"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1012"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1013"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1011"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1010"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="610"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1012"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1013"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1011"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1010"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="610"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1012"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1013"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1011"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1010"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="610"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1012"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1013"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1011"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1010"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="610"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1012"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1013"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1011"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1010"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="610"/>
              </event>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1012"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1013"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1011"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1010"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="610"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1012"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1013"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1011"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1010"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="610"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1012"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1013"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1011"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1010"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="610"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1012"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1013"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1011"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1010"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="610"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1012"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1013"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1011"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1010"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="610"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1012"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1013"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1011"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1010"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="610"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1012"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1013"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1011"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1010"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="610"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="377" subjects_at_risk="1008"/>
                <counts group_id="E2" subjects_affected="362" subjects_at_risk="1003"/>
                <counts group_id="E3" subjects_affected="357" subjects_at_risk="1004"/>
                <counts group_id="E4" subjects_affected="369" subjects_at_risk="1003"/>
                <counts group_id="E5" subjects_affected="190" subjects_at_risk="607"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="377" subjects_at_risk="1008"/>
                <counts group_id="E2" subjects_affected="362" subjects_at_risk="1003"/>
                <counts group_id="E3" subjects_affected="357" subjects_at_risk="1004"/>
                <counts group_id="E4" subjects_affected="369" subjects_at_risk="1003"/>
                <counts group_id="E5" subjects_affected="190" subjects_at_risk="607"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="152" subjects_at_risk="1008"/>
                <counts group_id="E2" subjects_affected="154" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="171" subjects_at_risk="1002"/>
                <counts group_id="E4" subjects_affected="185" subjects_at_risk="1003"/>
                <counts group_id="E5" subjects_affected="90" subjects_at_risk="607"/>
              </event>
              <event>
                <sub_title>Gastrointestinal symptoms</sub_title>
                <counts group_id="E1" subjects_affected="64" subjects_at_risk="1008"/>
                <counts group_id="E2" subjects_affected="63" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="70" subjects_at_risk="1002"/>
                <counts group_id="E4" subjects_affected="65" subjects_at_risk="1003"/>
                <counts group_id="E5" subjects_affected="36" subjects_at_risk="607"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="163" subjects_at_risk="1008"/>
                <counts group_id="E2" subjects_affected="162" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="155" subjects_at_risk="1002"/>
                <counts group_id="E4" subjects_affected="164" subjects_at_risk="1003"/>
                <counts group_id="E5" subjects_affected="80" subjects_at_risk="607"/>
              </event>
              <event>
                <sub_title>Joint pain</sub_title>
                <counts group_id="E1" subjects_affected="96" subjects_at_risk="1008"/>
                <counts group_id="E2" subjects_affected="84" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="74" subjects_at_risk="1002"/>
                <counts group_id="E4" subjects_affected="104" subjects_at_risk="1003"/>
                <counts group_id="E5" subjects_affected="57" subjects_at_risk="607"/>
              </event>
              <event>
                <sub_title>Muscle aches</sub_title>
                <counts group_id="E1" subjects_affected="165" subjects_at_risk="1008"/>
                <counts group_id="E2" subjects_affected="172" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="156" subjects_at_risk="1002"/>
                <counts group_id="E4" subjects_affected="195" subjects_at_risk="1003"/>
                <counts group_id="E5" subjects_affected="98" subjects_at_risk="607"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Concerns arose about data integrity for a Romanian site (102 subjects) after completion of analysis. These data were not excluded from this reporting as they did not reveal irregularities and GSK does not plan to use them towards regulatory filing.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

